Literature DB >> 32802408

Correction: AMG-232 sensitizes high MDM2-expressing tumor cells to T-cell-mediated killing.

Ilyas Sahin1,2, Shengliang Zhang1,3,4, Arunasalam Navaraj1,3, Lanlan Zhou1,3,4, Don Dizon1,2,4, Howard Safran1,2,4, Wafik S El-Deiry1,2,3,4.   

Abstract

[This corrects the article DOI: 10.1038/s41420-020-0292-1.].
© The Author(s) 2020.

Entities:  

Keywords:  Cancer immunotherapy; Drug development

Year:  2020        PMID： 32802408      PMCID： PMC7414103          DOI： 10.1038/s41420-020-00310-1

Source DB:  PubMed          Journal:  Cell Death Discov        ISSN： 2058-7716


Correction to: Cell Death Discovery 10.1038/s41420-020-0292-1 published online 6 July 2020 The original HTML version of this article was updated shortly after publication following a formatting issue which resulted in the abstract heading being omitted. This error has now been corrected in the HTML version of the Article. The PDF version of the Article was correct at the time of publication.
  1 in total

1.  AMG-232, a New Inhibitor of MDM-2, Enhance Doxorubicin Efficiency in Pre-B Acute Lymphoblastic Leukemia Cells.

Authors:  Abbas Ghotaslou; Amir Samii; Hassan Boustani; Omid Kiani Ghalesardi; Minoo Shahidi
Journal:  Rep Biochem Mol Biol       Date:  2022-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.